FDA announces immediate market withdrawal of Zantac/ranitidine medications

Apr 01, 2020 - 04:00 PM
fda-alert-recall-compounded-drugs

The Food and Drug Administration today announced it is requesting manufacturers immediately withdraw all prescription and over-the-counter ranitidine drugs (commonly known by the brand name Zantac) from the market.

This is the latest step in an ongoing investigation of the carcinogenic contaminant N-Nitrosodimethylamine (NDMA), which in some ranitidine products increases over time and when stored at higher than room temperatures to unacceptable levels.

The FDA advised consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine.

Related News Articles

Headline
FDA announces recall for certain IV bags
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
Recall issued for aspiration system by Q’Apel Medical
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
FDA issues alerts on certain catheters produced by BD, Conavi
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
AHA launches online collaborative focused on quality improvement
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
AHA webpage highlights how hospitals and health systems integrate patient safety
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…
Headline
FDA recalls Medtronic Aortic Root Cannulas 
The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of unexpected loose material in the male luer…